Processa Pharmaceuticals (PCSA) 10-K2019 FY Annual report

Filed: 6 Mar 20, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abbreviated, ACA, adult, adulteration, aimed, Akashi, Alberta, altered, altering, AMP, ANDA, anonymously, beam, beta, Bipartisan, BLA, block, Blueprint, bone, bore, born, bound, branch, broadly, Cadillac, Cantonese, carcinogenicity, category, charter, chemistry, Children, ChinaRock, Chinese, CHMP, closer, closure, CMS, CNS, collapse, column, compensatory, compliancewith, complicating, conceal, Concurrently, Congressional, contrast, COO, Cosmetic, Croatia, culture, Dear, Decentralized, defraud, denial, deplete, depressing, detention, developmental, diagnostic, distinct, district, DKBK, DMD, dossier, drawn, dual, Duchenne, Dystrophy, easier, ECs, EEA, encourage, English, entrenching, Equiniti, escalation, EU, exceeded, excise, expedient, expertise, FDCA, fiber, fibrotic, fluent, focal, footnote, forecast, formulary, fractional, Francisco, function, functional, functioning, gap, GCP, gender, Geraldine, GLP, GLTJ, harmonize, harmonizing, Harvard, healing, HHS, HIV, hypertension, Iceland, implicit, imprisonment, incentivize, incorrect, incremental, indebted, Ineffective, Inspector, interval, ion, Justice, land, landscape, lawfully, leaflet, length, lesion, Liechtenstein, Liu, LOC, MA, Mandarin, MAs, McKinsey, meantime, medicinal, membership, mild, mimic, misbranding, mismanaged, MMA, moiety, molecular, morbidity, mortality, multifamily, muscle, NCA, necessity, neurodegenerative, Norway, NYSE, outpatient, overseeing, pain, panel, Pannu, passed, payor, PDMA, PDUFA, permissible, pervasive, Ph, pharmacodynamic, physical, Pioneer, Poison, predated, predetermined, preempted, prolongation, prolonged, prorated, pulmonary, purity, QTc, qui, quotation, race, rarity, ratably, ratified, rationale, reaction, reauthorized, recommendation, recommended, recommending, reconsider, regeneration, regime, regimen, Relief, remuneration, repeal, repealed, repealing, reproductive, restitution, resubmitted, resubmitting, resume, reward, RMS, rolling, sampling, scheme, Scleroderma, Shanghai, Shanghainese, shelf, simultaneously, slight, SmPC, solicit, solid, somatic, sporadic, stability, stay, straight, strength, strong, student, subpopulation, substantive, substitution, Sunshine, Supplementary, surrogate, suspected, tam, Taxpayer, teaching, TGF, tier, timeframe, timeline, transient, transparency, transposed, Trump, Trust, Trustee, unconstitutional, undergo, undergoing, underwritten, unestablished, uniform, unissued, unrestricted, unwritten, upfront, verify, version, vertical, vi, vii, viral, visiting, week, welfare, willfully, window

Removed: agree, amend, arise, attributable, began, conflict, constituted, Finally, foregoing, HUWX, matured, minimal, occurrence, parent, proper, proxy, sued, thereto, training, unexercised

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PCSA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Processa Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2019 (the “Report”), David Young, as Chief Executive Officer of the Company, and James Stanker, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ David Young
David Young
Chief Executive Officer
March 6, 2020

/s/ James Stanker
James Stanker
Chief Financial Officer
March 6, 2020

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of § 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by § 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.